Want to see GB:CRTX full AI Analyst Report?
Top Page
Amur Minerals
(LSE:CRTX)
Select Model
Select Model
Rating:50Neutral
Price Target:
11.50 p
▲(0.00% Upside)
Action:Reiterated
Date:08/26/26
The score is held down primarily by weak financial performance (minimal revenue, recurring losses, and sustained cash burn), partially offset by zero debt. Technicals are constructive but look very overbought, which limits confidence in near-term entry. Corporate events are a clear positive due to Phase II trial progress and funding/grant support, while valuation remains challenged because profitability is negative and there is no dividend yield data.
Positive Factors
Zero financial debt
The absence of financial debt reduces refinancing exposure and avoids interest obligations that could further pressure a loss-making business. This gives Amur greater balance-sheet flexibility to preserve capital, pursue project work, or negotiate future funding without an existing lender burden.
Negative Factors
Minimal and inconsistent revenue
The lack of recurring revenue means the company currently has little operating income to fund exploration, development, or corporate costs. This leaves future value dependent on project advancement, asset transactions, or external financing rather than an established commercial revenue base.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero financial debt
The absence of financial debt reduces refinancing exposure and avoids interest obligations that could further pressure a loss-making business. This gives Amur greater balance-sheet flexibility to preserve capital, pursue project work, or negotiate future funding without an existing lender burden.
Read all positive factors
Amur Minerals (CRTX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£8.91M
Dividend Yield765.96%
Average Volume (3M)279.49K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue GrowthN/A
EPS Growth-157.14%
CountryUK
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding79,185,265
10 Day Avg. Volume168,791
30 Day Avg. Volume279,490
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.47
Price to Sales (P/S)0.00
P/FCF Ratio-2.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Amur Minerals Business Overview & Revenue Model
Company Description
CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumo...
How the Company Makes Money
null...
Amur Minerals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 19.98K | 56.88K | 0.00 | 0.00 |
| Gross Profit | -117.00K | 16.78K | -3.79K | 0.00 | 0.00 |
| EBITDA | -2.09M | -452.28K | -2.08M | -1.95M | -1.75M |
| Net Income | -1.90M | -485.05K | -247.74K | -2.45M | -1.54M |
Balance Sheet | |||||
| Total Assets | 1.80M | 1.82M | 160.53K | 23.89M | 31.24M |
| Cash, Cash Equivalents and Short-Term Investments | 1.13M | 1.28M | 1.26K | 2.90M | 4.93M |
| Total Debt | 0.00 | 0.00 | 496.75K | 0.00 | 0.00 |
| Total Liabilities | 381.00K | 341.00K | 920.19K | 765.65K | 1.13M |
| Stockholders Equity | 1.42M | 1.48M | 4.12M | 23.13M | 30.11M |
Cash Flow | |||||
| Free Cash Flow | -1.97M | -961.00K | -2.77M | -2.99M | -2.26M |
| Operating Cash Flow | -1.97M | -933.00K | -2.77M | -3.35M | -1.83M |
| Investing Cash Flow | -31.00K | 2.33M | 34.93M | -511.00K | 6.04M |
| Financing Cash Flow | 1.84M | -67.00K | -31.45M | 968.00K | 0.00 |
Amur Minerals Peers Comparison
UnderperformOutperform
Sector (51)
GB:CRTX
Amur Minerals
11.25
2.87
34.25%
GB:NFX
Nuformix Plc
0.17
0.05
47.32%
GB:CIZ
Cizzle Biotechnology Holdings PLC
1.50
-0.45
-23.08%
Amur Minerals Corporate Events
Business Operations and StrategyProduct-Related Announcements
CRISM Therapeutics Starts Phase II ChemoSeed Trial in Glioblastoma
Positive
Aug 20, 2026
CRISM Therapeutics has activated the first clinical site for its Phase II trial of irinotecan ChemoSeed in glioblastoma, marking a key step in moving its lead localised chemotherapy platform into active patient recruitment. The company’s imm...
Business Operations and StrategyProduct-Related Announcements
CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial
Positive
Aug 13, 2026
CRISM Therapeutics has completed the Site Initiation Visit at its lead NHS clinical trial site in the UK, clearing a key operational step toward starting patient recruitment for its Phase II study in the coming weeks. The trial will test irinoteca...
Business Operations and StrategyRegulatory Filings and Compliance
CRISM Therapeutics Reveals Concentrated Shareholder Base After Register Analysis
Positive
Jul 27, 2026
CRISM Therapeutics Corporation has disclosed the results of an independent shareholder register analysis, identifying investors with holdings of 3% or more of its ordinary share capital as of 30 June 2026. The largest disclosed shareholder is Mito...
Business Operations and StrategyExecutive/Board Changes
CRISM Therapeutics awards long-term share options to executive directors
Positive
Jun 30, 2026
CRISM Therapeutics has granted share options over ordinary shares to three directors under its existing EMI Share Option Plan, with awards reflecting personal performance in 2025 and 2026. The options, all struck at 10 pence, vest in thirds over t...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
CRISM secures key approvals and funding as ChemoSeed platform advances toward Phase 2
Positive
Jun 26, 2026
CRISM Therapeutics is a UK-based clinical-stage oncology company specialising in implantable drug delivery, led by its ChemoSeed platform for the localised and sustained delivery of chemotherapy to solid tumours such as high-grade glioma and prost...
Business Operations and StrategyProduct-Related Announcements
CRISM advances Phase 2 ChemoSeed trial for glioblastoma
Positive
Jun 25, 2026
CRISM Therapeutics said it has completed all manufacturing, quality, regulatory and study start-up work needed to begin treating patients in its Phase 2 trial of irinotecan ChemoSeed for glioblastoma. Clinical site activation is well advanced, wit...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingShareholder Meetings
CRISM Therapeutics Wins Shareholder Backing and Expands Capital Base After Funding Round
Positive
Jun 15, 2026
CRISM Therapeutics has secured shareholder approval at its general meeting for resolutions linked to a recently completed funding round, with all motions passed almost unanimously. The company says the proceeds, together with previously announced ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.